Hopeful treatment for COVID-19, remdesivir, which is made by Gilead Sciences, has entered a new stage of clinical trials. After findings revealed that remdesivir helps shorten the time patients are infected with coronavirus by four days, researchers now believe that when paired with anti-inflammatory drug interferon, that time will be reduced even further. A total of 1,000 participants in the phase III ACCT trial will receive either remdesivir and a placebo or remdesivir and beta interferon. Yourway has two decades of experience and a robust global footprint, which are key in clinical trial success.